Abrogation of immune complex glomerulonephritis by native carboxypeptidase and pharmacological antagonism of the C5a receptor

Jessy J. Alexander¹, Lee D. Chaves¹, Anthony Chang², Shruti Dighe¹, Alexander Jacob¹ and Richard J. Quigg¹

Activation of complement generates C5a which leads to signaling through C5aR1. This is tightly controlled, including by the plasma proteins factor H (FH) and carboxypeptidase N. Here we studied a chronic serum sickness (CSS) model of glomerulonephritis (GN) in which there is an active humoral immune response, formation of glomerular immune complexes (ICs), and resulting glomerular inflammation. The antibody response, glomerular IC deposition, the degree of GN, and consequent renal functional insufficiency in CSS were all worse in FH¹⁻²/² mice compared to wild-type FH¹/¹ animals. This was ameliorated in the former by giving a C5aR1 antagonist for the final 3 weeks of the 5-week protocol. In contrast, blocking CP-mediated inactivation of C5a increased these disease measures. Thus, complement regulation by both plasma FH and CP to limit the quantity of active C5a is important in conditions where the humoral immune response is directed to a continuously present foreign antigen. Signaling through C5aR1 enhances the humoral immune response as well as the inflammatory response to ICs that have formed in glomeruli. Both effects are relevant even after disease has begun. Thus, pharmacological targeting of C5a in IC-mediated GN has potential clinical relevance.

Keywords: C5a; carboxypeptidase N; factor H; glomerulonephritis

INTRODUCTION

The complement system provides a first line of defense against some microorganisms and participates in innate and adaptive immune responses to many others. More than 30 plasma and cell-associated proteins in three activation pathways converge on C3 and C5 to generate C3a, C3b, C5a, and C5b-9, each of which has biological activity. The receptors (R) for C3a and C5a are rhodopsin-like class A peptide G protein-coupled seven-span transmembrane Rs. The three extracellular loops of C3aR and C5aR1 confer ligand binding specificity while their activation is transduced through various αβγ G-proteins at the internal portion of the plasma membrane¹⁻². While traditionally considered pro-inflammatory on BM-derived cells, it is clear that C3aR and C5aR1 have a more widespread distribution with a variety of effects attributable to their activation³⁻⁵.

As it developed, the adaptive immune system incorporated the complement system, conferring C3/C5-binding proteins to lymphocytes and dendritic cells. For example, the B lymphocyte signaling complex contains complement receptor 2, which can be activated by immune complexes (ICs) containing natural antibody, foreign antigen, and activated C3, which then facilitates adaptive humoral responses to that antigen⁶. More recent evidence has shown an important role for complement in cellular immunity. Here, it appears the T cell and its antigen-presenting dendritic cell partner generate complement activation products, with signals through C3aR and/or C5aR1 affecting T cell proliferation and differentiation in normal T cell responses, as well as in autoimmunity and alloimmunity⁷⁻¹¹.

Productive complement activation could be considered as the successful generation of biologically active C3 and C5 products. For this to occur, the system must overcome several obstacles, not the least of which is time and space; that is, many of the biologically active intermediates have a very short period...
of time to find the next protein partner in sequence or suffer the fate of inactivation. There are also a host of complement regulatory proteins acting throughout the pathways. Spontaneous alternative pathway activation in the fluid phase is regulated by complement factor H (FH). The zinc metalloprotease, carboxypeptidase N (CPN), is released into serum as an active enzyme, where it potently deactivates C3a and C5a by removing their C-terminal arginine residues. Carboxypeptidase B2 is present in plasma as a thrombin-activatable proenzyme, which can also cleave C3a and C5a. The phosphatidylinositol-linked CPN is present in the kidney among other organs, where it potentially could also deactivate C3a and C5a.

Induction of chronic serum sickness (CSS) leads to deposition of ICs in glomeruli. Despite the substantial accumulation of ICs containing iC3b and IgG Fc (i.e., ligands for B2 integrins and FcγRs) wild-type C57BL/6 mice have little glomerular inflammation in CSS. In contrast, FH-deficient mice with CSS uniformly develop diffuse proliferative glomerulonephritis (GN) within 5 weeks. The GN in CSS is characterized by endocapillary inflammation, including with F4/80 macrophages around sites of ICs. The relevance for complement receptors in this model is C5aR1/FH−/− mice with CSS do not develop GN, while C5b1/FH−/− mice have exacerbated features of GN.

In studies using gene-targeted mice, the significant effects of C5aR1 on the immune response could not be separated from those in inflammation. Here we attempted to surmount this by administering a cyclic peptide antagonist (ant) of C5aR1 (PMX53, (Ac)Phe-[Orn-Pro-DCha-Trp-Arg], kindly provided by Dr John Lambris, University of Pennsylvania) was delivered at a dose of 25 µg/day via a mini-osmotic pump (Alzet) a regimen effective in our prior studies in lupus mice. This was started 2 weeks after immunization with apoferritin had begun, at which time clinically evident disease features were present (unpublished data). The mini-osmotic pump was changed weekly. To control for peptide administration delivered via mini-osmotic pumps, a cohort of FH−/− mice (n = 4) immunized with apoferritin received scrambled peptide on the same schedule. This did not affect disease features (BUN, GN scores) compared to FH−/− mice with CSS (n = 13) not given peptide. As such, these data were pooled. CPMinh (Plummer’s reagent, DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid, Calbiochem) was administered intraperitoneally at a dose of 1 mg every 12 hours starting 3 weeks after the start of daily apoferritin administration. After 5 weeks, animals were euthanized, and blood and tissues collected.

**Measurements from serum**

Blood urea nitrogen (BUN) concentrations were determined with a Beckman Autoanalyzer. Anti-apoferritin IgG was measured by ELISA. Polystyrene plates were coated with 5 µg/ml of apoferritin. After blocking with 1% (wt/vol) bovine serum albumin, plates were incubated with serial dilutions of serum samples or anti-horse ferritin (Jackson ImmunoResearch), followed by horseradish peroxidase-conjugated anti-mouse IgG (Kirkegaard and Perry Laboratories), and α-Phenylenediamine peroxidase substrate (Sigma-Aldrich). The data were presented as arbitrary units relative to a standard curve generated with anti-horse ferritin.

**Measurements from renal tissue**

Tissues were fixed in 10% buffered formalin and embedded in paraffin, from which 4 µm thick sections were cut and stained with periodic acid-Schiff. Slides were scored in a blinded manner by a renal pathologist (AC) for the extent of GN on a scale of 0 to 4 (in increments of 0.5) according to the schema of Passwell et al. as described previously.

About 4 µm sections from frozen mouse kidneys were fixed in ethanol:ether (1:1) for 10 minutes followed by 95% ethanol for 20 minutes, washed with PBS and stained with fluorescein anti-mouse C3 and rhodamine anti-mouse IgG (Cappel, MP Biomedicals). Slides were viewed with an Olympus BX-60 IF microscope. Representative photomicrographs were taken at identical settings with a Hamamatsu EM-CCD camera. Merged images were generated with NIH Image J software.

**Statistics**

Data were analyzed using Minitab statistical software (v. 16, College Park, MD, USA). Data sets were first analyzed with the Anderson-Darling normality test and considered parametric with H0 > 0.05. Parametric and non-parametric data are presented as mean ± SEM and median (Q1–Q3), respectively. All data presented graphically are from individual animals.
Parametric data were analyzed by one-way ANOVA with comparisons among groups using Tukey’s method. Non-parametric data sets were analyzed comparably by Kruskal–Wallis and Mood’s Median testing. Potential correlations among variables were first examined by calculating the Pearson product moment; those significant were further examined using the least-squares method.

RESULTS

Contrasting effects of inhibiting C5aR1 and CP on ICGN

We generated CSS by actively immunizing C57BL/6 FH−/− mice with a daily intraperitoneal dose of 4 mg horse spleen apoferritin (n = 36). As controls, FH−/− mice were treated identically, except apoferritin was omitted from the injections (n = 13). After 2 weeks of apoferritin administration, some mice received C5aR1ant (n = 7), CPinh (n = 8), or both (n = 4) until the conclusion of the study after 5 weeks of apoferritin or saline administration.

As shown in Figure 1, control FH−/− mice had normal renal function at the end of the 5-week experimental protocol as assessed by BUN levels of 27.9 ± 1.1 mg/dl. In contrast, FH−/− mice with CSS induced by repetitive apoferritin immunization had impaired renal function (BUN = 37.0 ± 2.2 mg/dl). This was also true of those mice receiving CPant (BUN = 39.7 ± 2.8 mg/dl). Renal insufficiency was prevented in FH−/− mice receiving C5aR1ant for the final 3-week period, whether or not CPinh was administered (BUN = 26.0 ± 0.6 and 27.2 ± 2.1 mg/dl, respectively). Thus, functional renal insufficiency in the CSS model can be prevented after disease onset by pharmacological blockade of C5aR1.

Histopathological features of ICGN were evaluated at the end of the 5-week experimental protocol (Figure 2). As in past studies, a minority (4 of 13) of control FH−/− mice (i.e., without CSS) had some glomerular inflammation with GN scores between 0.5 and 1.5 (Figure 2A and B). All FH−/− mice with CSS developed GN with 13 of 17 mice having scores of 1.5 or 2.0 (Figure 2A). The primary histopathological feature was of diffuse hypercellularity of the glomerular tufts (Figure 2C).

There was no evidence for thrombotic microangiopathy. As with BUN measurements, mice that received C5aR1ant for the final 3 weeks had significantly less GN (Figure 2D). Here, CPinh worsened GN (Figure 2E), including in those mice also receiving C5aR1ant. That the extent of GN was related to renal functional impairment is supported by the significant correlation between the two (BUN = 25.3 + (6.0 × GN); r = 0.63, P < 0.001). Thus, endocapillary diffuse proliferative GN occurring in this model relies upon C5aR1 signaling. These data illustrate that physiological complement regulation by FH and CP lessen the amount of C5a available to bind its receptor in states of IC deposition in glomeruli.

Effects of inhibiting CP on ICGN in wild-type mice

It appears when plasma FH is absent in FH−/− mice with CSS, there is sufficient productive generation of C5a to signal through C5aR1. Given the effects of CPinh on FH−/− mice with CSS, we investigated whether it would affect CSS in wild-type (i.e., FH+/+) mice. All control wild-type mice given saline instead of apoferritin (n = 8) had normal BUN values (<29.0 mg/dl) and no histopathological evidence of GN. Of the mice with CSS, 3 of 5 developed mild GN (score = 0.5) which was reflected by elevated BUN values (31.5–33.5 mg/dl). The mice with CSS also given CPinh had a small, but consistent increase in GN, with all five animals having GN scores 0.5–1.0 and BUN values ≥33.5 mg/dl (Figure 3). As with FH−/− mice with CSS, GN scores and BUN values were strongly correlated (BUN = 26.7 + (13.1 × GN); r = 0.75, P < 0.001), supporting the relevance and interrelatedness of these two measures. These data further support the importance of both FH and CP to limit C5a generation in pathological states of IC deposition.

Contrasting effects of inhibiting C5aR1 and CP on circulating and glomerular anti-apoferritin IgG

18, FH−/− mice with CSS had higher sera titers of anti-apoferritin IgG than wild-type FH+/+ mice (Figure 4). Interestingly, inhibition of C5aR1 from 3–5 weeks of immunization led to reduction of anti-apoferritin IgG to levels comparable to wild-type mice. Moreover, inhibition of CP led to a significant increase in anti-apoferritin IgG to levels comparable to wild-type mice. Thus, production of anti-apoferritin IgG in C57BL/6 mice appears to be fueled by C5a-C5aR1 in FH−/− mice even after the immune response has begun, which can be further increased by inhibiting CP-mediated inactivation of C5a.

**Figure 1** C5a-dependent renal functional impairment in FH−/− mice with CSS. CSS was induced in FH−/− mice by daily immunization with apoferritin, or saline alone as control. Groups of animals also received C5aR1ant and/or CPinh after 2 and 3 weeks, respectively. Shown are individual BUN values from all mice studied after 5 weeks. Data from each group were normally distributed. The horizontal lines are the mean value in each group. Groups were significantly different by ANOVA (P < 0.001). *P < 0.02 versus other three groups.
Double-label immunofluorescence microscopy was performed to evaluate glomerular IgG and C3 (Figure 5). As shown by the red staining in Figure 5B, FH<sup>−/−</sup> mice with CSS had IgG within mesangial regions (asterisks) with some extension to peripheral capillary walls (arrows). This was reduced in FH<sup>−/−</sup> mice with CSS given C5aR<sub>ant</sub> (Figure 5C), and worsened in mice given CP<sub>inh</sub> (Figure 5D). As anticipated, glomerular from FH<sup>−/−</sup> mice had linear glomerular capillary wall staining for C3; this was not appreciably affected by induction of CSS or either of the inhibitors (stained green in Figure 5).

DISCUSSION

To model IC-mediated GN, we induced CSS through active immunization with heterologous apoferritin as originally described by Stilman, Couser, and Cotran<sup>29</sup> and modified by Iskandar et al.<sup>31</sup> In this model, there is formation of glomerular ICs containing IgG and iC3b; these are ligands for inflammatory cell FcγRs and β<sub>2</sub> integrins, respectively. Even in experimental conditions resulting in a large burden of glomerular ICs, C57BL/6 mice with plasma FH have little glomerular inflammation<sup>19</sup>. In contrast, FH<sup>−/−</sup> mice are uniformly susceptible to GN<sup>18</sup>. In the absence of plasma FH, enough C3b escapes inactivation to form C5 convertases and generate C5a<sup>19</sup>. This leads to C5aR1 signals that are required for inflammatory cells to react to glomerular-bound ICs<sup>21</sup>. Here we show mice receiving C5aR<sub>ant</sub> for the final 3 weeks of CSS failed to develop GN and consequent azotemia.

Glomerular disease in CSS was indistinguishable between FH<sup>−/−</sup> mice treated with C5aR<sub>ant</sub> and wild-type FH<sup>+/+</sup> mice. Thus, blocking C5aR1 signals “normalizes” FH<sup>−/−</sup> mice. Our data allow the conclusion plasma FH is sufficient to block C5a production below that necessary for GN. Given the large burden of ICs in glomeruli in wild-type mice, we hypothesized some C3b escapes inactivation to facilitate generation of C5a; yet, the efficiency and overlapping nature of normal complement regulation was operative, with CP inactivating what C5a was generated. We confirmed this by showing treatment with CP<sub>inh</sub> exacerbated disease in wild-type mice. Even in states of considerable C5a generation, such as FH<sup>−/−</sup> mice with CSS, CP inactivation of C5a appears to limit disease.

Our accumulated data in CSS illustrate the tight regulation of both innate and adaptive immune systems<sup>18,21,22</sup>. Here we concentrated on the roles of FH and CP, which show the importance of signaling through C5aR1 in inflammatory disease. Downstream effects of C5aR1 include increasing FcγRIII avidity<sup>34,35</sup> and α<sub>Mβ<sub>2</sub></sub> integrin (complement receptor 3) ligand avidity<sup>34,35</sup>, allowing recognition of, and activation by IgG/iC3b-bearing ICs in the glomerulus. An elegant paradigm...
C5a in immune complex glomerulonephritis
JJ Alexander et al

C5a in immune complex glomerulonephritis
JJ Alexander et al

C5a in immune complex glomerulonephritis
JJ Alexander et al

C5a in immune complex glomerulonephritis
JJ Alexander et al

C5a in immune complex glomerulonephritis
JJ Alexander et al

Figure 4 C5a facilitates the humoral immune response in CSS. CSS was induced in wild-type (FH+/-) mice or FH-/- mice by daily immunization with apoferritin. Groups of animals also received C5aR1-sufficient or CP-sufficient mice, after 2 and 3 weeks, respectively. Shown are individual serum anti-apoferritin IgG values from all mice studied after 5 weeks. Data from each group were not normally distributed. The horizontal lines are the median values in each group. The boxes enclose Q1–Q3 intervals. Groups were significantly different by Kruskall–Wallis testing (P < 0.001), with between-group comparisons shown in the Figure. *P < 0.01 versus other three groups.

advanced and supported experimentally by Gessner et al is C5aR1 activation of Gα12 and phosphoinositide 3-kinase p110γ in mononuclear phagocytes leads to a transcriptional increase in FcyRIII and decrease in FcyRIIB through respective gene promoter “C5a-inductive” and “C5a-suppressive” regions36–38. This phenomenon is relevant in experimental disease models of liver, lung, and kidney (i.e., mesangial cells);38–40 clinically relevant is that blocking C5aR1 signals may underlie the therapeutic efficacy of intravenous immunoglobulin.41 Thus, by altering the balance between activating and inhibitory FcγRs on monocytes, C5aR1 can have a considerable impact on IC processing and its downstream effects.

We induce the CSS model through repetitive immunization with apoferritin without adjuvant. Animals generate an active anti-apoferritin IgG humoral immune response and deposit IgG in glomeruli, each of which can be quantified. In our prior studies, FH-/- mice with CSS had increased serum levels of anti-apoferritin IgG compared to wild-type controls, which we attributed to C5aR1 signaling, given equivalent anti-apoferritin IgG titers among wild-type and FH-/-/C5aR1-/-/- mice.21 This relationship was true for glomerular IgG as well, which was directly and positively correlated with anti-apoferritin IgG. Interestingly, here we have found comparable findings with pharmacological interventions in the final 3 weeks of the CSS model. That is, inhibiting C5aR1 led to lower serum anti-apoferritin IgG and glomerular IgG, while increasing intact C5a by blocking its inactivation by CP increased these two. While these data have been highly consistent relative to C5a/C5aR1 and FH, we must emphasize they minimize the intervening steps of IC processing involving plasma C4 and C3; erythrocytes bearing CR1 (primates) or platelets bearing FH (rodents); and FcyRIII and CR3 on mononuclear phagocytes. These are highly complex, as we have found in our studies with this CSS model17,40,21,22,42,43. The role for C5aR1 signaling to affect glomerular ICs was supported by studies by Falk and Jennette, in which C5-deficient mice had less glomerular ICs independent from the anti-apoferritin IgG response30 and by Wenderfer et al, in which C5aR1-deficient MRL/Fas39 lupus mice had lower quantities of glomerular ICs compared to C5aR1-sufficient controls44.

Arguably even more complex than the steps behind IC processing is the generation of a humoral immune response. It has
become clear that C5aR1 signals are relevant to adaptive immune responses in a variety of ways. From our circumstantial data, there is an anti-inflammatory (M2) macrophage population within the kidney that appears affected by C5aR1. In the active humoral immune response, signals through C5aR1 in both antigen-presenting cells and lymphocytes can promote Th1 and inhibit Treg responses.

Perhaps because the glomerular capillary wall contains acellular portions and is exposed to relatively large quantities of plasma proteins, it is particularly at risk of complement activation. In the C3 glomerulopathies, ineffective fluid phase complement regulation allows unrestricted C3 activation and deposition of C3 products in the glomerular capillary wall. FH also is retained by the glomerular capillary wall surface; when this is inefficient, endothelial cell injury and atypical hemolytic uremic syndrome can result. A comparable pathophysiology is believed to occur in Bruch’s membrane in the eye, accounting for the relationship between FH and age-related macular degeneration.

Pharmacologically targeting the complement system is now clinical reality. Because of the nature of complement activation, many inhibitors directed against a given complement protein also block successive steps in the activation pathway(s). For example, the anti-C5 antibody eculizumab prevents formation of C5a and C5b-9; the latter accounts for its therapeutic efficacy and now clinical use. Thus, it has been used in a number of past and present clinical trials, including in membranous nephropathy, lupus nephritis, atypical and Shigella infections, and anti-neutrophil cytoplasmic antigen-associated GN, diseases with a considerable range in phenotype. Identifying which among the limited number of active complement products are pathogenic in a given disease process is not a trivial point. Blocking those not directly relevant to disease will needlessly impair normal immunity as well as potential counterregulatory (anti-inflammatory) signals, for which there is growing evidence.

In summary, here we studied a GN model in which the humoral immune response is directed to a continuously present foreign antigen. It is directly relevant to GN occurring in humans in infectious illnesses (e.g., Streptococcus and Hepatitis C), as well as other IC-mediated GNs such as lupus nephritis, IgA nephropathy, and membranous nephropathy; each of which is characterized by an active humoral immune response, formation of glomerular ICs, and the resulting pathological effects. We show the importance of complement regulation by both plasma FH and CP to limit the quantity of active C5a. Signaling through C5aR1 enhances the humoral immune response as well as the inflammatory response to ICs that have formed in glomeruli. Both effects are relevant even after disease has begun. Thus, pharmacological targeting of C5a in IC-mediated GN has potential clinical relevance. This could readily be accomplished by blocking C5 cleavage with eculizumab.

**FUNDING SOURCE**

This work was supported by an endowment from Dr Arthur M. Morris, National Institutes of Health grant R01DK041873 to Richard J. Quigg, and by a grant from Kidneeds to Jessy J. Alexander.
C5a in immune complex glomerulonephritis
JJ Alexander et al.

19 Alexander JJ, Anzeiokoro OGB, Chang A, Hack BK, Markaryan A, Jacob A et al. Distinct and separable roles of the complement system in factor H-deficient bone marrow chimeric mice with immune complex disease. J Am Soc Nephrol 2006; 17: 1354–1361.

20 Alexander JJ, Wang Y, Chang A, Jacob A, Minto AW, Karmegam M et al. Mouse podocyte complement factor H - The functional analogue to human complement receptor 1. J Am Soc Nephrol 2007; 18: 1157–1166.

21 Alexander JJ, Chaves L, Chang A, Quigg RJ. The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice. Kidney Int 2012; 82: 961–968.

22 Alexander JJ, Chaves LD, Chang A, Jacob A, Ritchie M, Quigg RJ. CD11b is protective in complement-mediated immune complex glomerulonephritis. Kidney Int 2015. doi:10.1038/ki.2014.373. [Epub ahead of print]

23 Huber-Lang MS, Riedeman NC, Samra JY, YounkEM, MCGuire SR, Laudes JJ et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002; 16: 1567–1574.

24 Tamamis P, Kieslich CA, Nikiforovich GW, Woodruff TM, Morikis D, Archontis G. Insights into the mechanism of C5a inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking. BMC Biophys 2014; 7: 5.

25 Bao L, Osawa I, Pun T, Lambros JD, Haas M, Quigg RJ. C5a receptor deficiency attenuates T cell function and renal disease in complement factor H-deficient mice. Eur J Immunol 2005; 35: 3012–3020.

26 Huey R, Bloor CM, Kawahara MS, Hugli TE. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol 1983; 112: 48–60.

27 Younger JG, Sasaki N, Waite MD, Murray HN, Saleh EF, Ravidge ZB et al. Detrimental effects of complement activation in hemorrhagic shock. J Appl Physiol (1985) 2001; 90: 441–446.

28 Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002; 16: 424–428.

29 Stilmant MM, Couser WG, Cotran RS. Experimental glomerulonephritis in the mouse associated with mesangial deposition of autologous ferritin immune complexes. Lab Invest 1975; 32: 746–756.

30 Falk RJ, Jennette JC. Immune complex induced glomerular lesions in C5 sufficient and deficient mice. Kidney Int 1986; 30: 678–686.

31 Iskandar SS, Jennette JCW, Wilkman AS, Becker RL. Interstrain variations in nephrin protein of heterologous protein in mice. Lab Invest 1982; 46: 344–351.

32 Passwell J, Schreiner GF, Nonaka M, Beuscher HU, Colten HR. Local extrapathic expression of complement genes C3, factor B, C2 and C4 is increased in murine lupus nephritis. J Clin Invest 1988; 28: 1672–1684.

33 Skokowa J, Ali SR, Felda O, Kumar V, Konrad S, Shushakova N et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 2005; 174: 3041–3050.

34 Berger M, Budhu S, Le E, Li Y, Loike D, Silverstein SC et al. Different G(i)-coupled chemoattractant receptors signal qualitatively different functions in human neutrophils. J Leukoc Biol 2002; 71: 798–806.

35 Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003; 301: 1720–1725.

36 Konrad S, Engling L, Schmidt RE, Gessner JE. Characterization of the murine IgG Fc receptor III and IIB gene promoters: a single two-nucleotide difference determines their inverse responsiveness to C5a. J Biol Chem 2007; 282: 37906–37912.

37 Konrad S, Ali SR, Wiege K, Syed SN, Engling L, Piekarz RP et al. Phosphoinositide 3-kinase gamma and delta, linkers of coordinate C5a receptor-Fc gamma receptor activation and immune complex-induced inflammation. J Biol Chem 2008; 283: 33296–33303.

38 Kumar V, Ali SR, Konrad S, Zwerin J, Verbeek JS, Schmidt RE et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006; 116: 512–520.

39 Radeke HH, Janssen-Graalfs I, Sowa EN, Chouchakova N, Skokowa J, Loscher F et al. Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis. J Biol Chem 2002; 277: 27535–27544.

40 Shushakova N, Skokowa J, Schulman J, Baumann U, Zwerin J, Schmidt RE et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgRs in immune complex-induced lung disease. J Clin Invest 2002; 110: 1823–1830.

41 Konrad S, Baumann U, Schmidt RE, Gessner JE. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br J Haematol 2006; 134: 345–347.

42 Alexander JJ, Hack BK, Cunningham PN, Quigg RJ. A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor. J Biol Chem 2001; 276: 32129–32135.

43 Alexander JJ, Hack BK, Jacob A, Chang A, Haas M, Finberg RW et al. Abnormal immune complex processing and spontaneous glomerulonephritis in complement factor H-deficient mice with human complement receptor 1 on erythrocytes. J Immunol 2010; 185: 3759–3767.

44 Wenderfer SE, Ke B, Hoffmann TJ, Wetsel RA, Lan HY, Braun MC. C5a receptor deficiency attenuates T cell function and renal disease in MRL/lpr mice. J Am Soc Nephrol 2005; 16: 3572–3582.

45 Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant 2013; 28: 1685–1693.

46 Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulonephritis. Nat Rev Nephrol 2015; 11: 14–22.

47 Pickering MC, D’Agati VD, Nester CM, Smith RJ, Baumann U, Haas M et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079–1089.

48 Noris M, Capriolo J, Bresin E, Mossali C, Pianetti G, Gamba S et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844–1859.

49 Zipfel PF, Wolf G, John U, Kentouche K, Skerka C. Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytopenic purpura? Pediatr Nephrol 2011; 147: 1957–1966.

50 Naik A, Sharma S, Quigg RJ. Complement regulation in renal disease models. Semin Nephrol 2013; 33: 575–585.

51 Bradley DT, Zipfel PF, Hughes AE. Complement in age-related macular degeneration: a focus on function. Eye (Lond) 2011; 25: 683–693.

52 Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009; 373: 759–767.

53 Lapeyreque AL, Malina M, Fremaux-Bacchi V, Boppel T, Kirschfink M, Oualha M et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561–2563.

54 Mache CJ, chom-Roschitz B, Fremaux-Bacchi V, Kirschfink M, Zipfel PF, Roedt S et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312–1316.

55 Salant DJ. Targeting complement C5 in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2011; 22: 7–9.

This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/